More importantly, in the era of precision medicine, a highly specific c-Met inhibitor would be more suitable to fulfill the specific treatment need for sub-population of c-Met-driven cancer and serve as a “clean” component for combination strategies against c-Met-mediated drug resistance. This evidence concerns the gene MET and cancer.